Cargando…

Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Golinski, Marie-Laure, Vandhuick, Thibault, Derambure, Céline, Fréret, Manuel, Lecuyer, Matthieu, Guillou, Clément, Hiron, Martine, Boyer, Olivier, Le Loët, Xavier, Vittecoq, Olivier, Lequerré, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718016/
https://www.ncbi.nlm.nih.gov/pubmed/26714738
http://dx.doi.org/10.1186/s13075-015-0894-9
_version_ 1782410722990358528
author Golinski, Marie-Laure
Vandhuick, Thibault
Derambure, Céline
Fréret, Manuel
Lecuyer, Matthieu
Guillou, Clément
Hiron, Martine
Boyer, Olivier
Le Loët, Xavier
Vittecoq, Olivier
Lequerré, Thierry
author_facet Golinski, Marie-Laure
Vandhuick, Thibault
Derambure, Céline
Fréret, Manuel
Lecuyer, Matthieu
Guillou, Clément
Hiron, Martine
Boyer, Olivier
Le Loët, Xavier
Vittecoq, Olivier
Lequerré, Thierry
author_sort Golinski, Marie-Laure
collection PubMed
description BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. METHODS: RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNFα inhibitors. T and B cells from healthy controls (HC) were cultured with TNFα, and TNFα receptors neutralizing antibodies to highlight the TNFα effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively analyzed using the Proteome Profiler arrays and flow cytometry. RESULTS: In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was downregulated under TNFα inhibitors and upregulated under TNFα. In T cells from RA patients, RasGRP1 was decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNFα stimulation increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments have confirmed that the TNFα effect observed on T cells proliferation was due to the decrease of RasGRP1 expression. Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNFα and in B cells from HC leading us to conclude that RasGRP3 in B cells was modulated by TNFα. CONCLUSION: This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a biomarker linked to TNFα inhibitors. After binding to TNFR1, TNFα reduced RasGRP1 protein expression resulting in inhibition of T cell activation. TRIAL REGISTRATION: Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October 2005. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0894-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4718016
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47180162016-01-20 Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors Golinski, Marie-Laure Vandhuick, Thibault Derambure, Céline Fréret, Manuel Lecuyer, Matthieu Guillou, Clément Hiron, Martine Boyer, Olivier Le Loët, Xavier Vittecoq, Olivier Lequerré, Thierry Arthritis Res Ther Research Article BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. METHODS: RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNFα inhibitors. T and B cells from healthy controls (HC) were cultured with TNFα, and TNFα receptors neutralizing antibodies to highlight the TNFα effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively analyzed using the Proteome Profiler arrays and flow cytometry. RESULTS: In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was downregulated under TNFα inhibitors and upregulated under TNFα. In T cells from RA patients, RasGRP1 was decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNFα stimulation increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments have confirmed that the TNFα effect observed on T cells proliferation was due to the decrease of RasGRP1 expression. Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNFα and in B cells from HC leading us to conclude that RasGRP3 in B cells was modulated by TNFα. CONCLUSION: This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a biomarker linked to TNFα inhibitors. After binding to TNFR1, TNFα reduced RasGRP1 protein expression resulting in inhibition of T cell activation. TRIAL REGISTRATION: Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October 2005. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0894-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-26 2015 /pmc/articles/PMC4718016/ /pubmed/26714738 http://dx.doi.org/10.1186/s13075-015-0894-9 Text en © Golinski et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Golinski, Marie-Laure
Vandhuick, Thibault
Derambure, Céline
Fréret, Manuel
Lecuyer, Matthieu
Guillou, Clément
Hiron, Martine
Boyer, Olivier
Le Loët, Xavier
Vittecoq, Olivier
Lequerré, Thierry
Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title_full Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title_fullStr Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title_full_unstemmed Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title_short Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
title_sort dysregulation of rasgrp1 in rheumatoid arthritis and modulation of rasgrp3 as a biomarker of tnfα inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718016/
https://www.ncbi.nlm.nih.gov/pubmed/26714738
http://dx.doi.org/10.1186/s13075-015-0894-9
work_keys_str_mv AT golinskimarielaure dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT vandhuickthibault dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT derambureceline dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT freretmanuel dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT lecuyermatthieu dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT guillouclement dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT hironmartine dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT boyerolivier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT leloetxavier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT vittecoqolivier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors
AT lequerrethierry dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors